Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

The Journal of Dietary Supplements, published by TAYLOR & FRANCIS LTD, stands as a premier academic outlet in the fields of food science, nutrition, and pharmacology. With a notable impact factor reflecting its rigorous peer-review process and high-quality research, this journal serves as an essential resource for researchers, healthcare professionals, and students alike. Its indexed ISSN 1939-0211 and E-ISSN 1939-022X signify its dedication to disseminating cutting-edge studies and reviews, covering topics from dietary interventions to the efficacy of various supplements. Since its inception in 2008, the journal has emerged as a vital contributor to the scientific community, maintaining a Q2 rank in multiple categories, indicating its influence and reach. While it operates under a traditional subscription model, the journal’s commitment to advancing knowledge in nutrition and dietary science is evident in its comprehensive scope and a diverse array of high-impact articles. Located in the United States, the journal continues to invite submissions that will advance understanding and application of dietary supplements in enhancing health outcomes.

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.

Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.